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Cirrhosis with ascites is associated with impaired renal function accompanied by sodium and
water retention. Although it has been suggested thatmediators such as nitric oxide play a role
in the development of renal failure in this situation, other mechanisms underlying the
process are not well understood. This study examined the role of oxidative stress in mediat-
ing renal damage during the development of cirrhosis in order to understand mechanisms
involved in the process. It was shown that carbon tetrachloride– or thioacetamide-induced
cirrhosis in rats results in oxidative stress in the kidney as seen by increased lipid peroxida-
tion and protein oxidation, accompanied by altered antioxidant status. Cirrhosis was also
found to affect renal mitochondrial function, as assessed by measurement of the respiratory
control ratio, the swelling of mitochondria, and calcium flux across mitochondrial mem-
branes. Increased lipid peroxidation and changes in lipid composition were evident in the
renal brush border membranes, with compromised transport of 14C glucose across these
membranes. In conclusion, renal alterations produced as a result of cirrhosis in the rat are
possibly mediated by oxidative stress. (HEPATOLOGY 2006;43:1248-1256.)
End-stage cirrhosis results in marked alterations insystemic circulation and renal function. The al-tered systemic circulation is characterized by in-
creased cardiac output, plasma volume, and splanchnic
blood flow and by decreased peripheral resistance leading
to decreased mean arterial pressure.1,2 The progressive re-
duction in renal blood flow and glomerular filtration rate
and the impaired ability to excrete sodium and water lead
to ascites.3 Oxidative stress has been implicated in kidney
damage in several conditions, including treatment with
indomethacin,4 ischemia reperfusion injury,5 and dia-
betic nephropathy.6 Treatment with antioxidants has also
been shown to be effective in ameliorating renal injury in
renal artery stenosis7 and experimentally in renovascular
disease.8 Our earlier work showed that cirrhosis results in
oxidative damage in distal organs such as the intestine.9 In
patients with cirrhosis, renal function deteriorates as liver
function worsens, indicating a link between these two
organ systems.10 Apoptotic cell death and increases in
adenosine production (potentiating the vascular effects of
angiotensin-II) have been proposed to play a role in the
development of kidney damage during cirrhosis.11 Inhi-
bition of nitric oxide synthases significantly improves re-
nal function in cirrhotic animals, suggesting a role for
nitric oxide in renal pathophysiological events induced by
decompensated cirrhosis.12 It is now recognized that a
number of effects of NO are mediated through formation
of peroxynitrite.13 Generation of peroxynitrite from NO
requires the simultaneous presence of superoxide, which
is seen during oxidative stress. This led us to hypothesize
that the generation of free radicals and oxidative stress
during cirrhosis may result in oxidative damage in the
kidney. This hypothesis was tested in two experimental
models of cirrhosis using carbon tetrachloride (CCl4) or
thioacetamide (TAA) as the hepatotoxin.
Materials and Methods
Adenosine diphosphate (ADP), 3-[4.5-dimethyl thia-
zol-2-y;]-2,5-diphenyltetrazolium bromide (MTT),
1,1,3,3-tetramethoxy propane, Tris(hydroxymethyl)
aminomethane (Tris), N-[2-hydroxyethyl]peperazine-n-
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[2-ethanesulfonic acid] (HEPES), thiobarbituric acid
(TBA), dithio-bis-(2-nitrobenzoic acid) (DTNB), ar-
senazo III, succinic acid, iodo-nitro tetrazolium salt
(INT), xanthine, xanthine oxidase, O-dianisidine dihy-
drochloride, nicotinamide adenine dinucleotide (NAD),
reduced nicotinamide adenine dinucleotide phosphate
(NADPH), and hydroxy proline were obtained from
Sigma Chemical Co. (St. Louis, MO). Polyethylene gly-
col (PEG) 4000 was obtained from Fluka AG (Switzer-
land). 14C-labeled glucose was obtained from Bhaba
Atomic Research Center (Mumbai, India). Millipore mem-
branes (pore size 0.45) were obtained fromMillipore (In-
dia). Carbon tetrachloride and thioacetamide were obtained
from Qualigen Fine Chemicals, Ltd. (Mumbai, India), and
Spectrochem (Mumbai, India), respectively. All other chem-
icals and solvents used were of analytical grade.
Animals. AdultWistar rats of both the sexes (150-200
g), exposed to a daily 12-hour light/dark cycle and fed
water and rat chow ad libitum, were used for this study.
Rats were divided into four groups: Group I—control
(n  6); Group II—phenobarbitone controls (n  6 for
each of the five time periods, 1, 2, 3, 4, and 5 months,
total 30); Group III—phenobarbitone carbon tetra-
chloride treated (n 6 for each time period, total 30);
and Group IV—thioacetamide treated (n  6 for each
time period, total 30). This study was approved by the
Institutional Animal Ethics Committee (IAEC).
Induction of Cirrhosis in Rats. For rats in whom
cirrhosis was CCl4 induced, the CCl4 was administered
intragastrically. Control animals received no treatment.
Phenobarbitone controls received 35 mg/dL of tap water,
which was the only source of drinking water. The initial
dose of CCl4 was 40 L/rat, and subsequent doses were
adjusted on the basis of change in body weight as de-
scribed previously.9 For TAA-induced cirrhosis, rats were
administered intraperitoneal injections of TAA (200
mg/kg ip) in saline twice a week for 1, 2, 3, 4, or 5months.
Control rats received the vehicle alone.15 Animals were
sacrificed after 1, 2, 3, 4, or 5 months of CCl4 or TAA
treatment. For each treatment period, TAA-treated ani-
mals were sacrificed 1 week after stopping treatment, and
CCl4-treated animals were sacrificed 10 days after stop-
ping phenobarbitone.
Light Microscopy. Liver tissue was fixed in 10% buff-
ered formalin and processed. Four-micron sections were
cut and stained with hematoxylin and eosin and observed
under a light microscope.
Electron Microscopy. Renal tissue was fixed in 2.5%
glutaraldehyde, postfixed in osmium tetroxide, and em-
bedded in araldite (epoxy resin). One-micron-thick sec-
tions were cut and stained with toluidine blue. Suitable
areas for ultrastructural study were chosen after examin-
ing the 1- sections under the lightmicroscope. Ultrathin
sections of these areas were cut on an LKB UM4 ultrami-
crotome with a diamond knife (Diatome, Switzerland).
The sections were mounted on copper grids and stained
with uranyl acetate and lead citrate. The grids were exam-
ined under a Philips EM201C electron microscope
(Eindhoven, The Netherlands).
Estimation of Hydroxyproline. Hepatic hy-
droxyproline content was measured as described previ-
ously16 and expressed as micrograms of hydroxyproline
per gram wet weight of liver tissue.
Serum Parameters. Serum separated from blood ob-
tained by direct heart puncture was used for the assay of
alanine aminotransferase, aspartate aminotransferase, al-
kaline phosphatase, and total bilirubin as previously de-
scribed.17 Serum creatinine, serum osmolality, sodium,
and potassium were measured as previously described.18
Preparation of Mitochondria and Assessment of
Mitochondrial Function. Kidneys removed from the
experimental rats were washed with ice-cold saline and
decapsulated. Renal tissue was homogenized (5% w/v) in
buffer containing 220 mmol/L mannitol, 70 mmol/L su-
crose, 5 mmol/L Tris, and 1 mmol/L EGTA (pH 7.4).
The homogenate was used for the various assays and for
isolation of mitochondria by differential centrifugation as
described previously.19 The final mitochondrial pellet was
washed twice with a buffer containing 250 mmol/L su-
crose and 5mmol/L HEPES (pH 7.4) and was suspended
in the same buffer. Purity of the mitochondria was as-
sessed by measuring the marker enzyme succinate dehy-
drogenase. Mitochondrial function was assessed by
oxygen uptake, degree of swelling of mitochondria, and
MTT reduction as described earlier.4 Calcium flux was
measured by quantitating changes in the absorption spec-
trum of Arsenazo III at 675/685 nm. Arsenazo III is an
impermeable dye that indicates calcium concentration
outside mitochondria. On the addition of exogenous cal-
cium to a suspension of mitochondria, absorbance in-
creases initially because of the calcium binding to the dye.
However, this is a dynamic process, and as the mitochon-
dria take up calcium through the uniporter, external con-
centrations of calcium decrease, reflected in a decrease in
absorbance. The mitochondria were suspended in a me-
dium containing 250 mmol/L sucrose, 5 mmol/L
HEPES, 5 mmol/L succinate, and 40 M Arsenazo III
(pH 7.4). Calciumwas added to the reactionmedium at a
concentration of 10 mol/L in order to initiate the flux
studies.
Preparation of Renal Brush Border Membrane
Vesicles and Measurement of D-Glucose Uptake. Re-
nal tissue was minced and a 5% homogenate made in
buffer containing 2 mmol/L Tris-HCl and 50 mmol/L
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mannitol, pH 7.1, using a Porter-Elvelhem homogenizer,
following which the brush border membranes (BBMs)
were isolated as previously described.20 Purity of the iso-
lated BBMs was checked by enrichment of the marker
enzyme alkaline phosphatase.21 Isolated BBMs were as-
sessed for their ability to transport glucose by measuring
uptake using the rapid filtration technique at room tem-
perature, as previously described.22
Parameters of Oxidative Stress. The renal homoge-
nate, isolated mitochondria, and BBMs were used for the
assessment of parameters of oxidative stress. Malondial-
dehyde (MDA) was measured using the thiobarbituric
acid method.23 The amount of MDA formed was calcu-
lated from a standard curve prepared using 1,1,3,3 tetra
methoxypropane, and values were expressed as nanomoles
per milligram of protein. For measurement of conjugated
diene, total lipids were extracted as described previously,24
dissolved in 1 mL of heptane, read at 233 nm, and ex-
pressed as nanomoles per milligram of protein using a
molar absorption coefficient of 2.52  104. Protein car-
bonyl formed was measured using 2,4-dinitrophenyl hy-
drazine and calculated using amolar extinction coefficient
of 22 mM1cm1.25 Total thiol content was measured
using DTNB and expressed as nanomoles per milligram
of protein.26 Protein was estimated by Lowry’s method
using bovine serum albumin as a standard.27
Enzyme Assays. The activity of alkaline phosphatase
in the renal BBM was assayed using p-nitro phenyl phos-
phate as the substrate.21 Catalase,28 myeloperoxidase,29
glutathione peroxidase,30 and glutathione reductase31
were measured in the renal homogenate as described and
expressed as units per milligram of protein.
Analysis of Lipids. Renal BBM lipids were extracted
by the method of Bligh and Dyer.32 The lower organic
phase was concentrated using nitrogen, resuspended in a
small volume of chloroform/methanol (2:1), and used for
lipid analysis. Neutral lipids were separated on silica gel G
plates using the solvent system hexane/diethyl ether/ace-
tic acid (80:20:1, v/v). Spots corresponding to the stan-
dard were identified by iodine exposure and eluted.
Cholesterol, cholesteryl ester,33 triacylglycerol, and diac-
ylglycerol34 were quantitated as described. Fatty acid con-
tent was quantitated using gas chromatography as described
previously.35 Individual phospholipids were separated on a
silica gel H plate using the solvent system chloroform/meth-
anol/acetic acid/water (60:36:9.6:4.8, v/v) and quantitated
by phosphate estimation after acid hydrolysis.36
Statistical Analysis. Data are expressed as means 
SD. Statistical analysis was performed using the nonpara-
metric Mann-Whitney test. A P value of less than .05 was
taken to indicate statistical significance. Statistical calcu-
lations were performed using SPSS software forWindows
(version 9.0).
Results
Development of cirrhosis was confirmed by histology
and measurement of serum markers of liver injury in an-
imals treated withCCl4 andTAA.Control and phenobar-
bitone controls showed normal liver architecture after 3
months of treatment (Fig. 1A-B), whereas intragastric ad-
ministration of CCl4 showed micronodular cirrhosis with
extensive fibrosis after 3 months of treatment (Fig. 1C).
Serum markers for liver injury such as alanine amino-
transferase, aspartate aminotransferase, alkaline phospha-
tase, and total bilirubin were also found to be increased
significantly in rats treated with CCl4 after 3 months of
treatment (Table 1), accompanied by an increase in liver
hydroxyproline content, an indicator of fibrosis (Table 1).
Fig. 1. Light microscopy of liver from (A) control, (B) phenobarbitone
control, and (C) CCl4-induced cirrhotic rats after 3 months. (Original
magnification 30.) (D) Serum creatinine in CCl4- or TAA-treated rats at
1, 2, 3, 4, and 5 months compared with that of phenobarbitone-treated
controls. (E) Serum osmolality and (F) sodium after 3 months of CCl4
treatment compared with those of the phenobarbitone-treated controls.
*P  .05 compared to control.
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A similar trend was seen in TAA-treated rats.15 The serum
enzymes and liver hydroxyproline remained elevated even
after 5months of treatment, indicating that in this model,
frank cirrhosis was established by 3 months of treatment
and sustained at 5 months of treatment.
Animals treated with CCl4 developed ascites after 3
months of treatment, which was observed in 20%, 60%,
and 100% of the animal treated with CCl4 after 3, 4, and
5months of treatment, respectively, whereas the infection
of ascitic fluid was only seen in 60% of the animals after 5
months of CCl4 treatment. To check for renal function,
we looked at the osmolality and the levels of creatinine,
sodium, and potassium in the rat serum. Serum creatinine
was found to be increased by 3 and 5 months of CCl4
treatment and by 5 months of TAA treatment. Because
the maximum increase in creatinine was observed after 3
months of treatment, we measured serum osmolality, so-
dium, and potassium in CCl4-treated rats only for a
3-month period. Serum osmolality and sodium were
found to be increased significantly after 3 months of CCl4
treatment (Fig. 1D-F), but no difference in serum potas-
sium levels was observed (data not shown).
The ultrastructural appearance of renal tissue from
control rats treated with phenobarbitone alone appeared
to be within normal limits except for minimal swelling of
endothelial cells and occasional platelet or fibrin strands
in some of the capillary lumina in the glomeruli. After 3
months of phenobarbitone treatment alone, epithelial
and mesangial cells appeared to be within normal limits
(Fig. 2A). Proximal tubular epithelial cells showed focal
dilatation of mitochondria and endoplasmic reticulum,
associated with nuclear condensation and chromatin
clumping, which is suggestive of focal degenerative
change. Some of the tubular epithelial cells showed lipid
bodies (Fig. 2B) and reticulated material in their cyto-
plasm.
Ultrathin sections of kidneys from rats administered
CCl4 for 1-5 months showed more extensive tubular and
glomerular changes than did those of controls. After 3
months of CCl4 treatment, proximal convoluted tubules
showed patchy degenerative changes with mitochondrial
dilatation (Fig. 2C), nuclear crenation, and chromatic
condensation. Lipid, reticulated material, and mixed
lipid-reticulated bodies were seen inmany of the proximal
tubules of rats treated with CCl4. Additionally, some of
Table 1. Serum Markers for Assessing Liver Function in Carbon Tetrachloride–Treated Rats
Control
Carbon Tetrachloride Treatment
1 Month 3 Months 5 Months
Alanine amino transferase (IU/L) 144 3 158 7 630 46* 689 60*
Aspartate amino transferase (IU/L) 138 2.5 156 6 710 65* 756 52*
Alkaline phosphatase (IU/L) 87 10 97 10 415 44* 410 25*
Total bilirubin (mol/L) 17 4 18 4 65 3.5* 84 5*
Total protein (g/dL) 9.12 0.24 9.2 0.25 3.4 0.13* 3.2 0.2*
Hepatic hydroxyproline content
(g/g wet weight of liver tissue) 205 14 215 11 913 88* 1160 100*
*P  .05 compared with control.
Fig. 2. Electron micrographs of kidney from rats treated with phe-
nobarbitone alone and with CCl4. Rats treated with phenobarbitone alone
for 3 months showing (A) mild mitochondrial dilatation and (B) normal
glomeruli. Renal tissue after 3 months of CCl4 treatment showing (C)
mitochondrial dilation (arrow heads), (D) glomeruli changes with endo-
thelial cell swelling, (E) platelets (arrows), and (F) cytoplasmic bleb
formation (arrows).
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these tubules showed cytoplasmic edema. Glomeruli were
within normal limits in the first 2 months of treatment
but showed focal, segmental endothelial swelling in cap-
illaries at 3 months (Fig. 2D) and later. Visceral epithelial
cells were also swollen in some glomeruli. Platelets were
seen in some capillary lumina after 3 months of CCl4
treatment (Fig. 2E). Also, occasional platelet clusters were
seen in the peritubular capillaries. Some glomeruli
showed focal loss of endothelial fenestration and forma-
tion of cytoplasmic blebs (Fig. 2F) as well as intracyto-
plasmic myelin figures.
Oxidative stress was evident in the kidney, as seen by
increases in the parameters of oxidative stress, such as
malondialdehyde, conjugated diene, and protein carbon-
yls, and a decrease in thiol content in cirrhotic animals
after 3 months, compared with those in the phenobarbi-
tone controls. These changes were minimal at 1 and 2
months of treatment and were elevated until 5 months of
treatment with CCl4 or TAA (Fig. 3A-D). Myeloperoxi-
dase activity, a marker for neurophil infiltration, began to
increase in the kidney after 2 months of CCL4 or TAA
treatment and continued to increase until 5 months of
treatment (Fig. 3E). It was seen that catalase, glutathione
peroxidase, and glutathione reductase enzyme activities
were all decreased significantly after 3 months of CCl4 or
TAA treatment. These changes were apparent up to 5
months of treatment (Fig. 3F-H).
Mitochondria are another important source and target
of free radicals in the cell, and mitochondria in kidneys
from animals with cirrhosis were studied. There was func-
tional impairment of renal mitochondria in cirrhotic rats,
with a decreased respiratory control ratio, increased su-
peroxide production (measured by MTT reduction), al-
tered calcium flux across the mitochondrial membrane,
and mitochondrial swelling after 3 months of treatment.
These changes were apparent at 5 months as well (Fig.
4A-D). These biochemical measurements complement
the electron microscopy results, in which swollen mito-
chondria were evident in kidneys from animals with cir-
rhosis (Fig. 2C). Oxidative damage was also seen in renal
Fig. 3. Oxidative stress parameters—(A) malonaldehyde, (B) conju-
gated diene, (C) protein carbonyl content, (D) total thiol, (E) activity of
myeloperoxidase, (F) activity of catalase, (G) activity of glutathione
peroxidase, and (H) activity of glutathione reductase—in renal homoge-
nate from CCl4- or TAA-treated rats at 1, 2, 3, 4, and 5 months compared
with those of the phenobarbitone-treated controls. The assays were done
as described in the text. Each value represents the mean  SD of six
separate experiments. *P  .05 compared to control.
Fig. 4. Renal mitochondrial function and oxidative stress parame-
ters—(A) respiratory control ratio, (B) mitochondrial swelling, (C) MTT
reduction, (D) calcium flux, (E) malonaldehyde, (F) conjugated diene, (G)
protein carbonyl content, and (H) total thiol—from CCl4-treated rats at 1,
2, 3, 4, and 5 months compared with those of the phenobarbitone-
treated controls. The assays were done as described in the text. Each
value represents the mean  SD of six separate experiments. *P  .05
compared to control.
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mitochondria from cirrhotic rats, with an increase in ma-
lonaldehyde, conjugated diene, and protein carbonyls
content along with a decrease in thiol content compared
with those in the phenobarbitone controls (Fig. 5E-H).
All these changes were significant in rats treated for 3
months and in those that received CCl4 treatment for 5
months. All mitochondrial changes were also seen in
TAA-treated rats after 3 and 5 months (data not shown).
A decrease in alkaline phosphatase activity was seen in
renal BBMs after 3 months of CCl4 or TAA treatment
compared with that in the controls. This was accompa-
nied by oxidative stress, as evidenced by an increase in
peroxidation parameters (Fig. 5A-D). Renal BBM lipids
isolated from cirrhotic rats showed a decrease in triacyl-
glycerol and cholesterol content along with an increase in
diacylglycerol after 3 months of treatment compared with
those in the controls (Table 2). The levels of total free
fatty acids in the isolated renal BBMs of cirrhotic rats were
increased after 3 months of treatment as compared with
those in the controls (Table 2). Total phospholipids levels
were decreased in renal BBMs in cirrhotic animals after 3
and 5 months of CCl4 treatment compared with those in
the controls. Among the individual phospholipids, a
decrease in phosphatidylethanolamine and phosphati-
dylcholine accompanied by an increase in lysophos-
phatidylethanolamine and lysophosphatidylcholine was
seen (Table 2). The ratio of total cholesterol to total phos-
pholipids was lower in the BBMs isolated from cirrhotic
rats compared with that in the controls (Table 2). All the
lipid changes were still observed even after 5 months of
CCl4 administration. The functional integrity of the renal
BBM is also affected in cirrhosis, because the results
showed the ability to transport 14C glucose was impaired
significantly at 3 months of CCl4 administration com-
pared with that in the control, an effect that was seen even
at 5 months of treatment (14C D-glucose uptake at 20
seconds expressed as picomoles per milligram of protein
in controls versus CCl4-treated rats for 1, 3, and 5months
was 155  5.3 versus 140  9.7, 102  8.7, and 95 
Fig. 5. (A) Alkaline phosphatase activity and oxidative stress pa-
rameters (B) malonaldehyde, (C) conjugated diene, (D) protein carbonyl
content, and (E) glucose transport in renal brush border membranes
isolated from CCl4- or TAA-treated rats at 1, 2, 3, 4, and 5 months
compared with those of phenobarbitone-treated controls. The assays
were done as described in the text. Each value represents the mean 
SD of six separate experiments. *P  .05 compared to control.
Table 2. Lipid Composition of Renal Brush Border Membranes after Various Durations of CCl4 Treatment
Control
Carbon Tetrachloride Treatment
1 Month 3 Months 5 Months
Neutral lipids (nmol/mg protein)
Triacylglycerol 58 3 58 4 16 4* 7.8 2*
Diacylglycerol 20.5 2 20 3 31.25 3* 29.3 3*
Cholesterol 205 10 200 11 32.5 4* 25.94 2.9*
Cholesterol esters 76.7 4 64 2 70 3 69.36 5
Total free fatty acids 73.36 4.1 86.27 17.3 184 17* 256.3 17*
Phospholipids (nmol/mg protein)
Total phospholipids 422 7.2 426 5 380 6.5* 353 7*
Phosphatidylcholine 144 8 146 9 121 7* 82.6 6*
Phosphatidyl-ethanolamine 118 8 123.8 7 89.6 5.6* 77.5 4.5*
Lysophosphatidyl-choline 6.25 1 6.4 1 10.49 1.4* 13.9 1.2*
Lysophosphatidyl-ethanolamine 5.25 1 6.58 1.1 10.8 1.5* 18.4 1.3*
Cholesterol:phospholipid ratio 0.67 0.05 0.619 0.04 0.269 0.03* 0.26 0.03*
*P  .05 when compared to control
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4.5, respectively, P .05). The lipid alterations as well as
functional changes seen in the BBMs were also seen in
TAA-treated rats (data not shown). All these changes were
not prominent in the early stages of cirrhosis after 1 and 2
months of treatment. There was no significant difference
between the control and phenobarbitone controls in all
the assessed biochemical parameters .
Discussion
Renal failure has been observed in end-stage cirrhosis
because of intense renal vasoconstriction that frequently
develops in patients with cirrhosis and ascites.1 The wors-
ening of renal function and sodium andwater retention in
cirrhosis not only correlates with the elevation in plasma
vasopressin, renin, aldosterone, and norepinephrine, but
also with the degree of portal hypertension.1,10 Nitric ox-
ide and prostacyclin have been suggested to play roles in
renal damage during end-stage cirrhosis.37,38 In addition,
oxygen free radicals have been implicated in a wide variety
of renal diseases, including cyclosporine-induced nephro-
toxicity39 and diabetic nephropathy.6 Though the admin-
istration of antioxidants ameliorated renal dysfunction
and increased survival rates in patients with hepatorenal
syndrome,4 the role of oxygen free radicals in mediating
renal failure during cirrhosis has not been well examined.
This is important because these active species can initiate
a cascade of events that can have far-reaching conse-
quences. In fact, we previously demonstrated in an animal
model that cirrhosis results in oxidative stress in distant
organs such as the intestine,9 and this may also affect
bacterial translocation from the lumen of the gut (unpub-
lished observation). Oxidative stress gains additional im-
portance in the context of renal failure in cirrhosis,
because radicals such as superoxide can interact with ni-
tric oxide to generate peroxynitrite, which is an oxidant
and a nitrosating agent.14,41 Studies have shown that ni-
tric oxide synthase is increased in renal glomeruli of rats
with cirrhosis.42,43
Intragastric and intraperitoneal administration of
CCl4 and TAA, respectively, resulted in development of
cirrhosis by 3 months of treatment, with disruption of
normal liver architecture and fibrosis and fatty changes,
accompanied by elevation in serum markers of liver func-
tion. Significant oxidative stress was evident in the kidney
from cirrhotic animals, as seen by the increase in lipid
peroxidation parameters, evident by 3 months, when
frank cirrhosis was established. It has been demonstrated
that experimental cholestatic liver disease is associated
with increased lipid peroxidation in the kidney, brain,
and heart, suggesting that oxidative stress in cholestatic
liver disease is a systemic phenomenon, probably encom-
passing all tissues and organs, even those separated by the
blood-brain barrier.44 Our data now suggest that this may
also hold true in cirrhosis, at least in the intestine9 and
kidney.
Circulatory dysfunction in cirrhosis is predominantly a
result of arterial vasodilation in the splanchnic circulation
secondary to portal hypertension.10 Activation of the va-
soconstrictor system such as the renin-angiotensin-aldo-
sterone system, the sympathetic nervous system,
vasopressin, and endothelin has also been associated with
renal damage in cirrhosis.45 It has been suggested that
oxidative stress can have profound effects on hemody-
namics and renal function andmarkers of oxidative injury
such as F2-isoprostanes, and thiobarbituric acid reactive
substances are increased in renal venous circulation of bile
duct–ligated rats.46 Treatment with antioxidants such as
vitamin E prevents the renal dysfunction and normalized
mean arterial pressure, renal blood flow, glomerular filtra-
tion rate, and sodium and water retention in these ani-
mals,46 suggesting that oxidative stress functioned
upstream of all these alterations.
In the present study, the increase in serum creatinine
after CCl4 or TAA treatment suggests compromised renal
function in cirrhotic rats. Interestingly, the elevation in
serum creatinine was accompanied by an increase in se-
rum sodium and serum osmolality. Though hyponatre-
mia from sodium and water retention is common in end-
stage cirrhosis in humans, hypernatremia has been
reported in patients with hepatic failure.47
Ultrastructural studies of the kidneys of animals
treated with CCl4 showed mild mitochondrial dilatation
as well as tubular and glomerular changes in the first 2
months of treatment. From 3 months on swelling of en-
dothelial cells in the glomeruli was observed, which per-
sisted until 5 months. Endothelial cytoplasmic blebs in
the glomeruli suggest damage of these cells after 3 months
of CCl4 treatment. Platelets and occasional platelet clus-
ters were also seen in the capillary lumina after 3 months
of CCl4 treatment, suggesting damage to the vascular en-
dothelial cells in the glomeruli.
The kidney has a number of sources of free radicals,
including neutrophil infiltration and mitochondrial dys-
function. These were then examined in the kidney during
cirrhosis. Estimation of the activity of myeloperoxidase
indicates that neutrophil infiltration occurs in the kidney
by 3 months of treatment. These neutrophils may be one
source of free radicals, which ultimately lead to the lipid
peroxidation observed, because activated neutrophils gen-
erate oxygen free radicals and have been proposed to be a
major cause of the cell damage associated with many
chronic inflammatory diseases.48 Another important
source, as well as target for free radicals, is the renal mito-
chondria, which are also affected in cirrhosis. The uncou-
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pling of mitochondrial respiration and oxidative
phosphorylation in the kidney, resulting in the generation
of superoxide anions, has been observed in cirrhotic ani-
mals, suggesting this may be an alternate source of free
radicals in the kidney during the development of cirrho-
sis. A shift in the balance between free-radical production
and scavenging ability in tissues is a mechanism of oxida-
tive injury. The decreased levels of free-radical scavenging
enzymes such as catalase, glutathione reductase, and glu-
tathione peroxidase in the kidney in the cirrhotic rats is
further evidence of oxidative stress produced in the tissue.
The renal BBM is involved in excretion and absorption
of water, electrolytes, and small molecules across the
physiochemical gradient, and damage to this important
component could have far-reaching consequences for re-
nal function. Lipids are important components of bi-
omembranes, and any alteration in their composition
may bring about structural and functional changes in the
membrane. Biomembranes are major targets of oxidative
stress, and it was found that the renal BBMs of cirrhotic
rats showed increased levels of the products of peroxida-
tion, again indicative of oxidative damage to the kidney
during cirrhosis. This damage to the BBMswas associated
with altered transport function and lipid composition in
cirrhotic animals by 3 months of treatment that persisted
until 5 months of treatment. The decreases in the levels of
phosphatidylcholine and phosphatidyethanolamine,
along with the increases in the levels of the corresponding
lysophospholipids and free fatty acids in the renal BBMs
of cirrhotic animals, suggest the activation of the enzyme
phospholipase A2. It was previously demonstrated that
oxidative stress in the kidney can result in activation of
phospholipase A2.4 The decreased cholesterol/phospho-
lipids ratio seen in the BBMs isolated from cirrhotic rats
suggests increased fluidity of the membranes. Previous
studies from our laboratory have shown that oxygen free
radicals generated from ischemia/reperfusion injury in-
creased the fluidity of the intestinal brush border mem-
brane.49 It is also known that oxidative stress has been
suggested as being involved in renal BBM damage in di-
abetes50 and indomethacin toxicity,4 and our data indi-
cate that cirrhosis-induced renal oxidative stress may have
functional consequences of compromising transport
function across renal BBMs. The renal oxidative stress
observed in the CCl4- and the TAA-treated rats after 3
months of treatment was significant, and renal complica-
tions of cirrhosis such as hepatorenal syndrome develop
only during the end stage of the disease. This suggests that
oxidative damage in the kidney may occur prior to devel-
opment of complications such as hepatorenal syndrome.
All the changes seen in the kidney per se, as well as in
renal mitochondria and renal BBM were minimal after
the first and second months of treatment with this hepa-
totoxin and only became evident after the development of
frank cirrhosis, which occurred at 3months. This suggests
that initiation of kidney damage is a later event linked to
the progression of cirrhosis and rules out the possibility
that the changes seen in the kidney are a direct effect of the
hepatotoxin used in the model.
In conclusion, this study has shown that cirrhosis has
far-reaching consequences, resulting in the generation of
free radicals and oxidative damage in the kidney. Neutro-
phil infiltration and mitochondrial dysfunction probably
contribute to the generation of free radicals locally, which
in turn result in extensive lipid peroxidation. This affects
functional components of the kidney such as the brush
border membrane, which could have severe consequences
on organ function. These results suggest that oxygen free
radicals might play an important role in the development
of complications of cirrhosis such as renal damage.
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